LONG-TERM SAFETY AND EFFICACY OF 4-WEEKLY CERTOLIZUMAB PEGOL MONOTHERAPY AND COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM AN OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Fleischmann, R. [1 ]
van Vollenhoven, R. [2 ]
Vencovsky, J. [3 ]
Alten, R. [4 ]
Davies, O. [5 ]
Stach, C. [6 ]
de Longueville, M. [5 ]
VanLunen, B. [7 ]
Choy, E. [8 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA
[2] Karolinska Inst, Stockholm, Sweden
[3] Inst Rheumatol, Prague, Czech Republic
[4] Charite, Schlosspk Klin, D-13353 Berlin, Germany
[5] UCB Pharma, Brussels, Belgium
[6] UCB Pharma, Monheim, Germany
[7] UCB Pharma, Raleigh, NC USA
[8] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [31] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
    Kivitz, Alan
    Wells, Alvin F. F.
    Vargas, Juan I. I.
    Baraf, Herbert S. B.
    Rischmueller, Maureen
    Klaff, Justin
    Khan, Nasser
    Li, Yihan
    Carter, Kyle
    Friedman, Alan
    Durez, Patrick
    RHEUMATOLOGY AND THERAPY, 2023, 10 (04) : 901 - 915
  • [32] SAFETY AND EFFICACY OF BARICITINIB THROUGH 128 WEEKS IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Keystone, E.
    Taylor, P.
    Genovese, M.
    Schlichting, D.
    De La Torre, I
    Beattie, S.
    Rooney, T.
    Suters, A.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 26 - 26
  • [33] Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis
    Keystone, Ed
    Taylor, Peter
    Genovese, Mark
    Schlichting, Douglas
    de la Torre, Inmaculada
    Beattie, Scott
    Rooney, Terence
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1292 - 1292
  • [34] Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
    Josef S. Smolen
    Ronald van Vollenhoven
    Arthur Kavanaugh
    Vibeke Strand
    Jiri Vencovsky
    Michael Schiff
    Robert Landewé
    Boulos Haraoui
    Catherine Arendt
    Irina Mountian
    David Carter
    Désirée van der Heijde
    Arthritis Research & Therapy, 17
  • [35] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [36] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [37] Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
    Smolen, Josef S.
    van Vollenhoven, Ronald
    Kavanaugh, Arthur
    Strand, Vibeke
    Vencovsky, Jiri
    Schiff, Michael
    Landewe, Robert
    Haraoui, Boulos
    Arendt, Catherine
    Mountian, Irina
    Carter, David
    van der Heijde, Desire
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [38] Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
    Jürgen Wollenhaupt
    Eun-Bong Lee
    Jeffrey R. Curtis
    Joel Silverfield
    Ketti Terry
    Koshika Soma
    Chris Mojcik
    Ryan DeMasi
    Sander Strengholt
    Kenneth Kwok
    Irina Lazariciu
    Lisy Wang
    Stanley Cohen
    Arthritis Research & Therapy, 21
  • [39] Combination therapy with certolizumab pegol plus methotrexate maintains long-term efficacy in the treatment of rheumatoid arthritis: A 2-year analysis
    Keystone, Edward C.
    Schiff, Michael H.
    Mease, Philip
    van Vollenhoven, Ronald F.
    Desai, Chintu
    Smolen, Josef
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S529 - S529
  • [40] Long-Term Safety and Efficacy of Rotigotine in Patients with Idiopathic RLS: 5-Year Results from a Prospective Multinational Open-Label FollowUp Study
    Hogl, Birgit
    Trenkwalder, Claudia
    Garcia-Borreguero, Diego
    Kohnen, Ralf
    Poewe, Werner
    Stiasny-Kolster, Karin
    Bauer, Lars
    Fichtner, Andreas
    Schollmayer, Erwin
    Oertel, Wolgang
    NEUROLOGY, 2010, 74 (09) : A106 - A106
12345